Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

ts were at least 40 years old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, confirmed by radiographs, and diagnosed according to the ACR guidelines (patients must qualify as ACR global functional status I, II or III). Eligible patients were also current users of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or acetaminophen (paracetamol) for their osteoarthritis pain and these analgesics were withdrawn before treatment with study-drug. The study enrolled both hypertensive and non-hypertensive patients (50.3% of enrolled patients were hypertensive at baseline). There were no statistically significant differences among the four treatment groups for any baseline variables, including hypertension medical history.

About naproxcinod

Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United States during the first quarter of 2009.

NOTE: Within the framework of the ACR annual meeting held in Boston from November 6 to 11, 2007, NicOx had a corporate booth to introduce the Company and its technology to the scientific and medical community in the United States.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 de
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ITHACA, N.Y. , Aug. 22, 2014 /PRNewswire/ ... computed tomography (CT) imaging facility, is using the ... 4D and even 5D imaging to researchers and ... just launched, asks "What would YOU do if ... the possibility to researchers and explorers everywhere, from ...
(Date:8/22/2014)... 22, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... commercializes proprietary technologies and products for advanced microarray ... a Master Service Agreement to contract with a ... assays. During the initial phase of this agreement, ... working prototype of one of the customer,s assays, ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014  Vermillion, ... company focused on gynecologic cancers and women,s health, has ... of Sales and Managed Markets. Ms. Bauzon ... traction and expanding payer coverage for laboratory services companies. ... most recently with PerkinElmer, Inc., where she held the ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
(Date:8/22/2014)... treated for the cancer Hodgkin lymphoma will be able ... researchers estimated their risk of premature menopause with different ... Journal of the National Cancer Institute , are based ... in England and Wales treated for the cancer over ... research has suggested that women with Hodgkin lymphoma who ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Human induced ... field of regenerative medicine because they can be coaxed ... don’t always act as anticipated. They sometimes mutate, develop ... in a new study recently published in STEM CELLS ... around this, simply by removing the material used to ...
(Date:8/22/2014)... Thompson HealthDay Reporter ... American health-care workers infected with the deadly Ebola virus ... been released from the Atlanta hospital where they have ... Dr. Kent Brantly, 33, was released from Emory ... hospital Tuesday. Her family said the 59-year-old woman is ...
(Date:8/22/2014)... 22, 2014 Goats are taking over Beverly ... attends the 10th annual Pre-Emmy Awards Boom Boom Room. Celebrities ... the best new products for kids on August 23 at ... and we’ll be encouraging them to #GoGoat for L.A. families ... to present our gentle, non-GMO goat milk foods to health-conscious ...
(Date:8/22/2014)... 2014 Being optimistic about the ... some foreign and domestic companies are speeding up ... and acquisitions. In 2012, Medtronic, Inc. acquired the ... Kanghui Holdings for USD 816 million; In Jan. ... makers-- Trauson Holdings Company Limited for HKD5.9 billion; ...
Breaking Medicine News(10 mins):Health News:Scientists map risk of premature menopause after cancer treatment 2Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:Both U.S. Health-Care Workers Infected With Ebola Released From Hospital 2Health News:Both U.S. Health-Care Workers Infected With Ebola Released From Hospital 3Health News:#GoGoat with Kabrita at the Pre-Emmy Awards Boom Boom Room 2Health News:China Orthopedic Instrument Industry 2014- Global Industry Size, Share, Trend, Growth and Forecast 2017 2
... Host Free Webcast on Making a Smooth Transition to the ... Incorporated (NYSE: IRM ), the global leader in ... share tips during an upcoming Webcast for how healthcare providers ... , In this free, hour-long Webcast, attendees will learn the ...
... researcher says , THURSDAY, June 4 (HealthDay News) -- ... the world don,t perform as well as males in math. ... the United States and abroad that appears in the June 1 ... , "There are countries where the gender disparity in math ...
... June 4 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: ... and services to the global life sciences markets, today ... financial results on Thursday, June 11, 2009. , The ... analysts with Stephen P. DeFalco, President and Chief Executive ...
... , , Proven Interoperability Solution Expands ... Carestream, Intergy RIS, Cloverleaf, Meditech RIS, McKesson, PowerScribe ... June 4 Healthcare IT workflow management pioneer ... its comprehensive suite of Enterprise digital imaging and ...
... plans reduce audit risk while ensuring accurate payments and compliance with ... a select few have ever wondered how to integrate Medicare Risk ... hear about the latest release from Storan Technologies Inc. ... of Merlin Medicare Risk Adjustment 6.0 (TM), a ...
... relief for pain, strengthening of immune systems and more , ... more research is showing that most illness, disease and other ... of the cellular immune system with essential nutrition. Key to ... nutrients and water. This is something that,s become more difficult ...
Cached Medicine News:Health News:Best Practices for Hospitals Moving to Electronic Medical Records 2Health News:Girls and Math: Blame the Culture, Not Ability 2Health News:Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution 2Health News:Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution 3Health News:Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution 4Health News:St. Louis Firm Brings Medicare Risk Adjustment to iPhone 2Health News:Breakthrough Nanotechnology Delivers Safe, Nutrition-Packed Cellular Hydration 2Health News:Breakthrough Nanotechnology Delivers Safe, Nutrition-Packed Cellular Hydration 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: